CelLBxHealth has released a first quarter trading update for the three months to end March 2026. The period reflects the ongoing operational transformation within the business, most notably additional actions to right‑size the cost base, including further headcount reductions, with these activities expected to reduce annual cash operating costs by £6.6m during 2026. Cash at end‑1Q was £4.3m, in-line with expectations. While notable progress has been made in the internal transformation as the bus ....
